|
| Press Releases |
|
 |
|
| Tuesday, June 8, 2021 |
|
|
Eisai: New Data on LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Versus Sunitinib |
| Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth, N.J., U.S.A. announced new investigational data from the pivotal Phase 3 CLEAR(Study 307)/KEYNOTE-581 trial, which evaluated the combinations of LENVIMA. more info >> |
|
| Monday, May 31, 2021 |
|
|
Eisai and ITO EN Enter Into Business Alliance Aiming to Support People Living with Dementia and to Prevent Dementia |
| Eisai Co., Ltd. and ITO EN, LTD. announced today that both parties have entered into a business alliance agreement concerning the initiatives for supporting people living with and preventing dementia with the aim of realizing a healthy and long-lived society. more info >> |
|
| Thursday, May 20, 2021 |
|
|
Eisai to Present Data on Oncology Pipeline and Products at ASCO Annual Meeting |
| Eisai Co., Ltd. announced today that the latest data regarding its oncology pipeline and products including in-house discovered lenvatinib mesylate and eribulin mesylate will be presented at the American Society of Clinical Oncology (2021 ASCO Annual Meeting*), to be held virtually from June 4 to 8, 2021. more info >> |
|
| Wednesday, May 19, 2021 |
|
|
Anticancer Agent "Remitoro Intravenous Drip Infusion 300 microgram" (Denileukin Diftitox (Genetical Recombination)) Launched in Japan |
| Eisai Co., Ltd. announced today that it has launched the anticancer agent ?Remitoro? for Intravenous Drip Infusion 300 microgram (Denileukin Diftitox (Genetical Recombination)) with the indications of relapsed or refractory Peripheral T-cell Lymphoma (PTCL) and relapsed or refractory Cutaneous T-cell Lymphoma (CTCL), in Japan. more info >> |
|
| Friday, May 14, 2021 |
|
|
Eisai and National Cancer Center Commence Joint Research and Development Project |
| Eisai Co., Ltd. and the National Cancer Center Japan announced today that both parties have entered into a joint research and development (R&D) agreement concerning "Basic research on the drug discovery and development to accelerate development of anticancer drugs in treatment of patients with rare cancers and refractory cancers", and that research activities have commenced. more info >> |
|
| Tuesday, May 11, 2021 |
|
|
Eisai's Statement of Commitment for Carbon Neutrality by 2040 |
| Eisai Co., Ltd. announced today that it has pledged to reduce greenhouse gas (GHG) emission which causes global warming, with an aim to achieve carbon neutral, and has set its new medium- to long-term target for achieving the goals. more info >> |
|
| Friday, May 7, 2021 |
|
|
Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Receive Priority Review From FDA for LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Applications |
| Eisai Co., Ltd.and Merck & Co., Inc., Kenilworth, N.J., U.S.A. today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review for applications seeking two new approvals for the combination of LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, plus KEYTRUDA, the anti-PD-1 therapy from Merck & Co., Inc., Kenilworth, N.J., U.S.A. more info >> |
|
| Wednesday, April 28, 2021 |
|
|
RESONA and Eisai Enter Into Business Alliance Aiming to Support People Living with Dementia and to Prevent Dementia in Saitama Prefecture, Japan |
| Saitama Resona Bank, Limited, a corporation of the Resona Group, and Eisai Co., Ltd. announced today that both parties have entered into a business alliance agreement for building an ecosystem. more info >> |
|
| Friday, April 23, 2021 |
|
|
Eisai: Application Submitted for Additional Indication of Anti Cancer Agent Lenvima in Combination With Keytruda as a Treatment for Advanced Uterine Body Cancer in Japan |
| Eisai Co., Ltd. and MSD K.K. announced today an application submission in Japan for the additional indication of Eisai's in-house discovered and developed multiple receptor tyrosine kinase inhibitor, LENVIMA. more info >> |
|
|
Eisai: Gilead Sciences Submits New Drug Application in Japan for Filgotinib for the Treatment of Ulcerative Colitis with an Inadequate Response to Conventional Therapies |
| Gilead Sciences K.K. and Eisai Co., Ltd. today announced that Gilead submitted an application to Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for approval of filgotinib for an additional indication to treat patients with moderately to severely active ulcerative colitis. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Assembly Unifies APAC Network Under One Brand to Build Asia's Leading Tech-Powered Brand Performance Agency
Jan 13, 2026 10:00 HKT/SGT
|
|
|
Germany Buys Eight MQ-9B SeaGuardian(R) RPA Through NSPA
Jan 13, 2026 07:00 HKT/SGT
|
|
|
OBI Pharma and TegMine Therapeutics Sign Exclusive Global License Agreement for Glycan-Targeting ADC
Jan 12, 2026 20:00 HKT/SGT
|
|
|
Charlie's Holdings (OTCQB:CHUC) Signs Agreement with IKE Tech to Commercialize Transformational Age-Gated Vapes that Will Address FDA Concerns Related to Youth Access
Jan 12, 2026 19:00 HKT/SGT
|
|
|
Toys & Games Fair, Baby Products Fair and Stationery & School Supplies Fair open today
Jan 12, 2026 18:26 HKT/SGT
|
|
|
Mazda Unveils MAZDA CX-6e New Battery EV in World Premiere
Jan 12, 2026 13:10 JST
|
|
|
Argentine Football Association (AFA) teams with Verofax to offer AI Experiences to Fans 
Jan 12, 2026 10:00 HKT/SGT
|
|
|
Metaspacex Limited Partners with Popcorn Technology to Expand into Web3.0 Digital Finance
Jan 11, 2026 20:59 HKT/SGT
|
|
|
PromiCell, Inc. presents during JP Morgan's 2026 Healthcare Conference
Jan 10, 2026 07:00 HKT/SGT
|
|
|
TOYOTA GAZOO Racing Announces GR Yaris MORIZO RR
Jan 9, 2026 16:03 JST
|
|
|
Honda Announces New Lines of Models that Represent "Honda Sports DNA" at Tokyo Auto Salon 2026
Jan 9, 2026 14:24 JST
|
|
|
Honda Launches Fixed-Battery Electric Two-Wheeled Personal Commuter "Honda UC3" in Thailand and Vietnam
Jan 9, 2026 13:27 JST
|
|
|
Sponsorship Agreement Reached with LCR Honda; Full-Season MotoGP Entry as Pro Honda LCR
Jan 9, 2026 13:05 JST
|
|
|
Mazda Develops New Body Color, "Navy Blue Mica"
Jan 9, 2026 10:23 JST
|
|
|
Fujitsu develops digital learning platform for JAL to support self-directed learning and training management
Jan 9, 2026 10:07 JST
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
